This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sitaras, N. M. Articles by Antoniades, H. N. Search for Related Content PubMed PubMed Citation Articles by Sitaras, N. M. Articles by Antoniades, H. N.

Constitutive Production of Platelet-derived Growth Factor-like Proteins by Human Prostate Carcinoma Cell Lines¹

Division of Biological Sciences, Harvard School of Public Health [N. M. S., M. B., P. P., H. N. A.]; Laboratory of Clinical Pharmacology, Dana Farber Cancer Institute, Harvard Medical School [E. S.]; and the Center for Blood Research [P. P., H. N. A.], Boston, Massachusetts 02115

Prostate carcinoma cell lines DU-145 and PC-3 express both platelet derived growth factor (PDGF)-1 and PDGF-2/sis genes. Concomitantly, these cells synthesize and secrete PDGF-like proteins, as judged by indirect immunofluorescence and by direct immunoprecipitation with specific PDGF antiserum. Conditioned media derived from DU-145 and PC-3 cells stimulated the incorporation of [³H]thymidine by 3T3 cells and competed with ¹²⁵I-labeled PDGF for its binding to cell surface receptors of 3T3 cells. The biological activity was stable to heating at 100°C for 10 min, sensitive to reducing agents, and neutralized by the IgG fraction of PDGF antiserum, properties similar to those of authentic PDGF. Both DU-145 and PC-3 cell lines appear to lack receptors for PDGF as indicated by their inability to mitogenically respond to PDGF and receptor binding of ¹²⁵I-labeled PDGF. Production of PDGF-like proteins by human prostate carcinoma cells may play an important role in a paracrine mode in the organization of the extracellular matrix of the malignant tissue.

¹ Supported by USPHS Grants CA38784 (P. P.), CA30101, and HL29583 (H. N. A.) and by the Council for Tobacco Research (H. N. A.).

² Fellow of the National Council of Science and Technology of Mexico ("CONACYT").

³ To whom requests for reprints should be addressed.

Received 8/25/87. Revised 12/23/87. Accepted 1/ 6/88.

This article has been cited by other articles:

				S. M. Apte, D. Fan, J. J. Killion, and I. J. Fidler Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma Clin. Cancer Res., February 1, 2004; 10(3): 897 - 908. [Abstract] [Full Text] [PDF]

				H. Uehara, S. J. Kim, T. Karashima, D. L. Shepherd, D. Fan, R. Tsan, J. J. Killion, C. Logothetis, P. Mathew, and I. J. Fidler Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases J Natl Cancer Inst, March 19, 2003; 95(6): 458 - 470. [Abstract] [Full Text] [PDF]

				E. Buchdunger, C. L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B. J. Druker, and N. B. Lydon Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 139 - 145. [Abstract] [Full Text]

				S. M. Sintich, M. L. G. Lamm, J. A. Sensibar, and C. Lee Transforming Growth Factor-{beta}1-Induced Proliferation of the Prostate Cancer Cell Line, TSU-Pr1: The Role of Platelet-Derived Growth Factor Endocrinology, August 1, 1999; 140(8): 3411 - 3415. [Abstract] [Full Text]

				R. L. Panek, G. H. Lu, S. R. Klutchko, B. L. Batley, T. K. Dahring, J. M. Hamby, H. Hallak, A. M. Doherty, and J. A. Keiser In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1433 - 1444. [Abstract] [Full Text]

				T. K. Dahring, G. H. Lu, J. M. Hamby, B. L. Batley, A. J. Kraker, and R. L. Panek J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1446 - 1456. [Abstract]